Today: 29 June 2026
CBA share price slips as ASX selloff bites; Commonwealth Bank results and rate changes ahead
6 February 2026
1 min read

CBA share price slips as ASX selloff bites; Commonwealth Bank results and rate changes ahead

Sydney, Feb 6, 2026, 16:54 AEDT — After-hours

  • Shares of Commonwealth Bank ended Friday at A$158.91, slipping 0.23%
  • The ASX 200 fell 2%, marking its biggest drop in nearly a year
  • Investors are turning their attention to the Feb. 11 results and rate adjustments expected in mid-February

Shares of Commonwealth Bank of Australia (CBA.AX) slipped 0.23% to close at A$158.91 on Friday, after trading in a range from A$156.95 to A$160.08. Investors appeared to reduce exposure heading into the weekend.

The stock broke a five-day winning streak as the S&P/ASX 200 plunged 2%, closing sharply down. “Panic is spreading,” said MooMoo Australia analyst Michael McCarthy to ABC, noting how markets are dropping in sync. ABC News

Rate jitters have crept back into Australian bank shares. Tuesday saw the Reserve Bank of Australia hike its cash rate to 3.85%. The country’s big four banks — CBA, Westpac, National Australia Bank, and ANZ — wasted no time, pushing up variable mortgage rates starting mid-February.

CBA revealed its repricing schedule on Friday. The bank’s GoalSaver bonus rate is set to increase by 0.25 percentage points, reaching 4.50% annually. For new customers, the NetBank Saver introductory rate will climb to 4.70%. Both rate changes kick in on Feb. 13, coinciding with a 0.25-point hike in variable home-loan rates.

This is crucial since net interest margin—the difference between what banks earn on loans and what they pay out for funding—can shift quickly when deposit rates rise. Investors are watching to see if higher mortgage rates can compensate for the rising costs banks face in attracting deposits.

The lender has ramped up its focus on technology. In a Thursday AI report, CEO Matt Comyn noted stakeholders want a clearer picture of “how AI is being used across the Bank” and how potential risks are managed. Executive general manager Alex Matthews emphasized that trust remains “fundamental” to CBA’s strategy. CommBank

The wider market offered little support. U.S. stocks slipped on Thursday, dragged down by renewed selling in major tech names as investors grew skeptical about the returns from heavy AI investments and grew wary of growth stocks.

Even for a bank often seen as a defensive play, risks remain. Rising rates could hit mortgage repayments, pushing arrears higher. Add in tougher deposit competition, and funding costs might climb faster than expected, putting pressure on margins.

The next major event is Feb. 11, when CBA will release its half-year results and hold a webcast briefing at 10:30 a.m. AEDT. The bank has already flagged a A$68 million pre-tax provision related to the ASIC Better Banking review, along with A$53 million in non-recurring income items that will impact the comparisons.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • AbbVie Stock Surges, Boosting Valuation of $10.9 Billion Apogee Acquisition
    June 28, 2026, 6:38 PM EDT. AbbVie Inc. shares climbed 4.2% to a 52-week high of $253.35 on June 26, lifting the company's market value by approximately $65 billion since June 18. This surge is nearly six times the $10.9 billion cash price AbbVie is paying for Apogee Therapeutics. The acquisition, financed through debt, includes Apogee's late-stage IL-13 antibody zumilokibart for atopic dermatitis. Despite a 49% premium paid over Apogee's June 18 close, AbbVie expects a reduced adjusted earnings per share (EPS) in 2026 and 2027, with accretion only anticipated by 2032. Investors appear focused on AbbVie's long-term immunology growth, with key drugs Skyrizi and Rinvoq generating $6.6 billion in Q1 revenue. AbbVie's CEO described the deal as creating significant long-term shareholder value.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next
Previous Story

NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop